ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Other Events

Item 8.01. Other Events.

On April 10, 2017, OncoMed Pharmaceuticals, Inc. (the Company)
issued a press release announcing top-line results from the
Companys randomized Phase 2 YOSEMITE clinical trial of demcizumab
(anti-DLL4, OMP-21M18) in combination with Abraxane (paclitaxel
protein-bound particles for injectable suspension) (albumin
bound) plus gemcitabine in previously untreated patients with
metastatic pancreatic cancer as well as a conference call/webcast
to review these results (the Demcizumab Press Release). A copy of
the Demcizumab Press Release is attached to this Current Report
on Form 8-K as Exhibit 99.1. In the Demcizumab Press Release, the
Company reported that the Phase 2 YOSEMITE trial did not meet the
primary endpoint of progression-free survival and that the
interim median overall survival analysis did not show a benefit
for demcizumab in combination with Abraxane plus gemcitabine
compared to the Abraxane, gemcitabine plus placebo arm in
patients with first-line metastatic pancreatic cancer. The
Company also reported that it will be discontinuing the Phase 2
YOSEMITE trial and will conduct additional analyses, together
with its partner for demcizumab, Celgene Corporation, to
understand the outcomes of the Phase 2 YOSEMITE trial. The
Company further reported that it will also discontinue any
additional enrollment in its other ongoing clinical trials of
demcizumab and will conduct analyses of the data from those
trials as planned.

Also on April 10, 2017, the Company issued a press release
announcing that Bayer Pharma AG had notified the Company of its
decision not to exercise its option to license vantictumab
(anti-Fzd, OMP-18R5) and ipafricept (Fzd8-Fc, OMP-54F28) (the
Bayer Press Release). A copy of the Bayer Press Release is
attached to this Current Report on Form 8-K as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

About ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED)

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company’s Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company’s Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.

ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Recent Trading Information

ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) closed its last trading session down -0.10 at 8.76 with 331,979 shares trading hands.